Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Fatal evolution of a renal angiosarcoma].

Pedro López Cubillana1, Enrique Martínez Barba, Gerardo Server Pastor

  • 1Servicio de Urología. Hospital "Virgen de la Arrixaca", 30120-El Palmar, Murcia, España. pedrolopezcubillana@hotmail.com

Archivos Espanoles De Urologia
|July 24, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA class-I genotyping to personalize Bacille Calmette-Guerin immunotherapy in bladder cancer.

Oncoimmunology·2025
Same author

Interplay of KIR2DL5, nitric oxide, and tobacco smoking in predisposition to bladder cancer.

Frontiers in cell and developmental biology·2025
Same author

Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies.

Biomedicines·2025
Same author

Exploring the Immunoresponse in Bladder Cancer Immunotherapy.

Cells·2024
Same author

Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study.

Journal of clinical medicine·2024
Same author

Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study.

Prostate international·2024

This case report details a rare renal angiosarcoma in a 72-year-old male. Despite surgery and chemotherapy, the patient experienced metastasis and succumbed to the disease, highlighting the poor prognosis of renal angiosarcoma.

Area of Science:

  • Oncology
  • Pathology
  • Surgical Oncology

Background:

  • Primary renal angiosarcoma is an exceptionally rare malignancy.
  • Fewer than 10 cases were documented in literature prior to 1998.
  • The condition is characterized by a consistently poor prognosis.

Observation:

  • A 72-year-old male presented with a renal tumor, subsequently diagnosed as renal angiosarcoma post-nephrectomy.
  • The patient developed widespread bone and lung metastases within three months of surgery.
  • Symptoms included lumbar pain and hemoptysis.

Findings:

  • The renal angiosarcoma exhibited aggressive behavior with rapid metastatic progression.
  • Systemic chemotherapy using Doxorubicin and Ifosfamide demonstrated no therapeutic response.

Related Experiment Videos

  • Immunohistochemical studies, utilizing markers such as CD31, CD34, and Factor VIII related antigen, are crucial for confirming endothelial differentiation.

    • Implications:

    • This case underscores the dismal prognosis associated with primary renal angiosarcoma.
    • Current therapeutic strategies for renal angiosarcoma are not well-established due to its rarity.
    • Further research is needed to define optimal treatment approaches for this aggressive tumor.